Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fluconazole on Pyrotinib Pharmacokinetics in Healthy Chinese Adults
NCT04850651Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrotinib in HER2-positive breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Observed Plasma Concentration of Pyrotinib at Day 9, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration at Day 9 and 1 more. Started Apr 2021; status: completed.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04850651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850651.